CD274 and cancer: Immune checkpoint inhibitor (ICI) therapy, which includes antibodies targeting cytotoxic T lymphocyte-associated protein-4 (CTLA-4), programmed death-1 (PD-1), and programmed death ligand-1 (PD-L1), offers significant clinical benefits for patients with many types of cancer [1–3].